Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.65 -0.24 (-0.93%)

Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,700 in Passive Income in 2026 ↗

January 18, 2026

Making passive income isn't easy, but it's achievable with these stocks.

Via The Motley Fool

The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS) ↗

January 17, 2026

All three of these stocks sport dividend yields above 6%.

Via The Motley Fool

Topics Intellectual Property

Top Picks 2026: Pfizer Inc. ↗

January 17, 2026

As we head into 2026, healthcare stands out as one of the most dislocated areas of the market. One of our favorite ideas within the sector is Pfizer Inc., which has climbed its own crowded wall of...

Via Talk Markets

Wall Street’s Comeback King: Citigroup Shatters M&A Records as Jane Fraser Sets a High Bar for 2026

January 16, 2026

Citigroup Inc. (NYSE: C) has emerged from its multi-year restructuring with a historic performance in its investment banking division, reporting record-breaking M&A advisory revenue for the 2025 fiscal...

Via MarketMinute

Topics Artificial Intelligence Economy

Most active S&P500 stocks in Tuesday's session ↗

January 13, 2026

Via Chartmill

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Topics Initial Public Offering Intellectual Property Lawsuit

NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? ↗

January 16, 2026

The United Kingdom’s Medicines and Healthcare products Regulatory Agency on Friday announced that it had approved a maximum dose of up to 7.2 milligrams a week for Novo’s Wegovy earlier this month.

Via Stocktwits

3 Cash-Producing Stocks with Questionable Fundamentals

January 15, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...

Via StockStory

1 Healthcare Stock Worth Your Attention and 2 We Avoid

January 15, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have...

Via StockStory

Topics Stocks

1 Profitable Stock with Solid Fundamentals and 2 We Brush Off

January 15, 2026

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Via StockStory

Topics Bankruptcy

"Animal Spirits" Return: Morgan Stanley Signals M&A Renaissance as Healthcare and Industrials Lead Shifting Landscape

January 15, 2026

As 2026 begins, the global mergers and acquisitions (M&A) market is witnessing a profound "renaissance," driven by a confluence of stabilizing interest rates, record levels of corporate cash, and a...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

These S&P500 stocks are the most active in today's session ↗

January 15, 2026

Via Chartmill

The Execution Engine: How Merck is Dominating the 2026 Pharma Landscape

January 15, 2026

As of January 15, 2026, Merck & Co. (NYSE: MRK) has emerged as the standout performer in the pharmaceutical sector, defying the gravity of looming patent expirations with a series of strategic...

Via MarketMinute

Topics Economy Intellectual Property

Healthcare Titan Ascendant: Johnson & Johnson Hits All-Time Highs as It Navigates a New Political and Clinical Era

January 15, 2026

As of January 15, 2026, Johnson & Johnson (NYSE: JNJ) has emerged as the undisputed pacesetter of the healthcare sector, with its stock price surging to an all-time high of $218.53. This milestone...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Earnings

3 Volatile Stocks We Keep Off Our Radar

January 14, 2026

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

Via StockStory

Curious about the most active S&P500 stocks in today's session? ↗

January 14, 2026

Via Chartmill

The Great Tariff-Inflation Tug-of-War: Why the Fed’s 2% Target Remains Elusive in 2026

January 14, 2026

As the United States enters the first quarter of 2026, the global economy is grappling with a radical shift in trade dynamics that has upended decades of globalization. The aggressive...

Via MarketMinute

Topics Economy Supply Chain World Trade

Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation

January 14, 2026

Date: January 14, 2026 Viatris Inc. (NASDAQ: VTRS) stands at a critical crossroads in early 2026. After years of functioning as a complex, debt-laden conglomerate formed from the massive merger of...

Via Finterra

Topics Earnings Economy Intellectual Property

Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot

January 14, 2026

Once the poster child for the biotechnology sector’s rapid response to the global pandemic, Moderna, Inc. (Nasdaq: MRNA) finds itself at a critical crossroads in early 2026. After a tumultuous period...

Via Finterra

Topics Initial Public Offering Intellectual Property

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 14, 2026

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Via The Motley Fool

Topics Intellectual Property

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Via PredictStreet

Topics Economy Intellectual Property

The Evolution of a Giant: A Deep Dive into the ‘New’ Johnson & Johnson (JNJ) in 2026

January 13, 2026

As of January 13, 2026, Johnson & Johnson (NYSE: JNJ) stands at a pivotal juncture in its nearly 140-year history. Once a sprawling conglomerate synonymous with baby shampoo and Band-Aids, the "New...

Via PredictStreet

Topics Artificial Intelligence Bankruptcy Economy

3 Value Stocks That Fall Short

January 12, 2026

Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices. But these hidden gems are few...

Via StockStory

Why Tempus AI Stock Rose Today ↗

January 12, 2026

The data provider's artificial intelligence-driven solutions are accelerating drug discovery.

Via The Motley Fool

Topics Artificial Intelligence

The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape

January 12, 2026

As the 44th Annual J.P. Morgan Healthcare Conference concludes in early January 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a critical crossroads. Once the darling of the pandemic era, the...

Via MarketMinute

Topics Economy Intellectual Property World Trade

Pfizer CEO Eyes Big Push Towards Obesity Drug Development In 2026 After $10B Metsera Acquisition ↗

January 12, 2026

Pfizer’s CEO Albert Bourla is looking to initiate about 10 late-stage trials of the company’s new obesity drugs.

Via Stocktwits

Stay informed about the most active stocks in the S&P500 index on Monday's session. ↗

January 12, 2026

Via Chartmill

Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial ↗

January 12, 2026

Pfizer shared new trial data showing its cancer drug combo helped shrink tumors more often than standard treatment in advanced colorectal cancer patients at a major oncology meeting.

Via Benzinga

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.